Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Professor Claudia Monaco, of the Kennedy Institute, is the 2015 Oxford-Harrington Scholar.

As a clinician-scientist, Professor Monaco has dedicated her career to the discovery of new treatments for cardiovascular disease (CVD). Her work was pioneering in looking at CVD within the area of inflammation, using a unique approach to test efficacy in human atherosclerosis – a condition where arteries become blocked by fatty substances.

CVD is a big health problem and the second leading cause of death in the UK, representing 28% of all deaths in 2012. In addition, there were more than 1.6 million episodes related to cardiovascular disease in NHS hospitals, with more than £6.8 billion being spent on treating CVD within the NHS in England.

Professor Monaco’s research aims to change standard of care and improve health for people with CVD, by bringing new medicines into the clinical setting.

The Oxford-Harrington Scholarship Programme was set up in 2014 as a partnership between the Harrington Discovery Institute (Cleveland, USA) and the University of Oxford to advance highly promising Oxford supported drug discovery projects.

The rate of drug development is now slower than it used to be, with pharmaceutical companies and investors waiting to invest until the efficiency of a drug has been confirmed. This leaves a gap in the intermediate stages of research and development and has discouraged clinical scientists from pursuing their ideas.

The Oxford-Harrington Scholarship will close this gap by supporting clinical scientists whose ideas have great potential to become new treatments, with pre-clinical drug research and clinical trials in the early stages. It will also provide the drug development infrastructure needed to turn a discovery into a medicine.

The first Oxford-Harrington scholar was Professor Alison Simmons, whose aims were to undertsnad how inflammation damages the gut in Crohn’s disease, a condition that affects 1 in 200 people.

You can read more about the 2015 Oxford-Harrington Scholar here.

 

Similar stories

Professor Dani Prieto-Alhambra elected to ISPE Board of Directors

Dani Prieto-Alhambra, Professor of Pharmaco- and Device Epidemiology at NDORMS, has been elected as the Academic representative for Europe and Africa on the International Society of Pharmaco-Epidemiology Board of Directors.

New research from the Kennedy Institute of Rheumatology identifies a role for CD200 in limiting atherosclerosis

A new study published in Circulation Research shows that CD200, an inhibitory immune checkpoint, reduces the development of atherosclerosis.

EPSRC funds research to avert an antibiotics apocalypse

Researchers at the Kennedy Institute join a collaboration to find new ‘drug-free’ ways of treating illnesses where current treatments have become ineffective due to antibiotic resistance.

Research finds that surgery for Dupuytren’s disease is effective, but repeat operations come with higher risks

Research by NDORMS Dominic Furniss, Professor of Plastic and Reconstructive Surgery, finds that surgery for the common hand disorder Dupuytren’s disease is safe and effective. However, repeat surgery could carry higher risks of complications such as finger amputation.

Celebrating World Clubfoot Day

More than 30,000 children in Africa are born with clubfoot each year. With treatment simply not available where they live, many thousands of these children get no treatment and end up with severe deformities that make it hard and very painful to walk.

Repurposed drug can induce remission of inflammatory arthritis

Researchers at the Kennedy Institute demonstrate that the drug decitabine can boost regulatory T cell responses.